ITEM METADATA RECORD
Title: Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice
Authors: Vande Casteele, Niels ×
Gils, Ann #
Issue Date: Mar-2015
Publisher: Wiley-Blackwell Publishing, Inc.
Series Title: Journal of Clinical Pharmacology vol:55 Suppl 3 pages:S39-50
Article number: 10.1002/jcph.374
Abstract: Since anti-tumor necrosis factor (TNF) antibodies were introduced to treat patients with inflammatory bowel diseases, short- and long-term clinical and endoscopic endpoints can be achieved that were unreachable with conventional anti-inflammatory agents. Although a large proportion of patients (70-90%) initially respond to the treatment, remission rates after induction are still low (20-50%) and patients are at risk to lose response to the drug over time. This inter-individual variability in response is likely to be influenced by the observed inter-individual variability in pharmacokinetics. By extensively reviewing the literature, we evaluated the potential role of therapeutic drug monitoring to optimize dosing of anti-TNF drugs. Thereby we emphasize some of the pharmacokinetic cornerstones that can help to understand the observed concentration-effect relationship. After discussing some of the most commonly used assays to measure anti-TNF drug and anti-drug antibody concentrations, we reviewed the application of those tests and their potential clinical value in retrospective and prospective studies.
ISSN: 0091-2700
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Therapeutic and Diagnostic Antibodies (+)
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy

 




All items in Lirias are protected by copyright, with all rights reserved.

© Web of science